AVH
data caveat$201M—
AVITA Medical
Medical Devices · Wound care
Commercial-stage regenerative medicine company whose RECELL System delivers FDA-approved Spray-On Skin for burn wounds, full-thickness skin defects, and vitiligo repigmentation.
Data HealthTrials2 of 2 active · stale enrollment
No cash data on fileFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
—
Runway
—Market Cap
$201M
Burn Rate
—
Shares Outstanding
153M
Pipeline Assets
9
3M Price
AVH.ASX$1.315+12.9% 3M
Low $1.075High $1.525
Pipeline Assets (9)
Cohealyxfull-thickness wound repair
Phase 2PermeaDermtemporary wound coverage
Phase 2Cohealyxfull-thickness wound preparation
Phase 2PermeaDermsurgical wound coverage
Phase 2RECELL Systemburn wounds
ApprovedRECELL GOburn wounds and full-thickness skin defects
ApprovedCapital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Short Interest
ASIC ↗as of 2026-03-27 · 4-day lag
Short position
0.18%
arrow_drop_up+0.04% over 2 reports
Shares short
0.2M
Aggregated short position data published by ASIC under the Corporations Act. T+4 reporting lag applies. Short interest ≥5% is noteworthy; ≥10% is elevated. Source: ASIC Short Selling Data
Competitive Landscape
1 approved drug52 competitor trialsPhase 2+ · Non-ASX
Full-Thickness Wound Repair9 active trials
2 Ph42 Ph34 Ph21 Ph1/PHASE2
Burn Wounds40 active trials
11 Ph410 Ph31 Ph2/39 Ph29 Ph1/PHASE2
Approved
Full-Thickness Skin Defects2 active trials
2 Ph2
Stable Vitiligo Repigmentation1 active trial
1 Ph2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
expand_moreClinical Publications
Peer-reviewed papers & conference abstracts via PubMed
3 papers
Clinical Publications
Peer-reviewed papers & conference abstracts via PubMed
Front Cell Dev Biol2026-01· RECELL System
Mil Med2025-12· RECELL System
J Burn Care Res2025-08· PermeaDerm
Catalysts (25)· 7 upcoming · 18 past
Cohealyx I clinical study data readout
UpcomingExpectedremoveMed30 June 2026
Cohealyx I study data readout
UpcomingExpectedarrow_upwardHigh30 June 2026
Final MAC reimbursement coverage
UpcomingExpectedarrow_upwardHigh30 June 2026
7th MAC reimbursement rate publication
UpcomingConfirmed
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
0/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
⚠ TIMELINE CHANGESCT.GOV · AUTO-DETECTED
These changes were automatically detected by comparing ClinicalTrials.gov records over time. A slipped date means the trial's expected completion moved later; pulled forward means it moved earlier.
★ RESULTS
Clinical Trials(3)
2 activeClinicalTrials.gov ↗
NAActive Not RecruitingEnrollment stale · 425d
PermeaDerm Biosynthetic Wound MatrixFrozen Human Cadaveric Allograft (FHCA)
Randomized Controlled Trial to Investigate Clinical Outcomes and Associated Costs When PermeaDerm is Used as Temporary Dressing for Surgical Wounds
Surgical Wound · Trauma Wound · Autografts +2 more
RandomizedOpen Label
Primary endpoint Reduction of Cost per Total Body Surface Area (TBSA)
NAActive Not RecruitingEnrollment stale · 342d
Cohealyx
Multicenter Single-arm Trial to Investigate Clinical Outcomes When Cohealyx™ is Used for Full Thickness Wounds
Burn · Trauma Wound · Full Thickness Wounds +1 more
Primary endpoint Time for Cohealyx to generate tissue capable of supporting definitive closure